Skip to main content
Erschienen in: Der Onkologe 2/2010

01.02.2010 | In der Diskussion: Komplementäre Onkologie

Komplementärer Seleneinsatz in der Onkologie

verfasst von: Dr. R. Mücke, L. Schomburg, J. Büntzel, U. Gröber, P. Holzhauer, O. Micke

Erschienen in: Die Onkologie | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das essenzielle Spurenelement Selen hat eine erhebliche Bedeutung für die menschliche Gesundheit. Als Bestandteil selenabhängiger Proteine ist die Mitbeteiligung an Stoffwechselprozessen, v. a. im Rahmen der endogenen antioxidativen Abläufe, essenziell und gut charakterisiert. Sowohl in vitro als auch in vivo liegen Daten für eine positive Beeinflussung durch Supplementation von Selen im Rahmen der Krebsprävention und bei der Reduktion von Nebenwirkungen durch Strahlen- und Chemotherapie vor. Weltweit erstmalig konnte nun die radioprotektive Wirkung von Selen ohne negative Beeinflussung des Gesamtüberlebens durch eine randomisierte radioonkologische Studie belegt werden. In einer kürzlich vorzeitig beendeten US-amerikanischen Studie zur Primärprävention des Prostatakarzinoms war der Einsatz von Selen eher wirkungslos. Wir geben eine Einschätzung dieser Ergebnisse und einen aktuellen Überblick über die neuen Erkenntnisse einschließlich konkreter Empfehlungen für den klinischen Einsatz.
Literatur
1.
Zurück zum Zitat Beck MA, Nelson HK, Shi Q et al (2001) Selenium deficiency increases the pathology of an influenza virus infection. FASEB J 15:1481–1483PubMed Beck MA, Nelson HK, Shi Q et al (2001) Selenium deficiency increases the pathology of an influenza virus infection. FASEB J 15:1481–1483PubMed
2.
Zurück zum Zitat Bleys J, Navas-Acien A, Guallar E (2008) Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 168:404–410CrossRefPubMed Bleys J, Navas-Acien A, Guallar E (2008) Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 168:404–410CrossRefPubMed
3.
Zurück zum Zitat Blot WJ, Li JY, Taylor PR et al (1993) Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population. J Natl Cancer Inst 85:1483–1489CrossRefPubMed Blot WJ, Li JY, Taylor PR et al (1993) Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population. J Natl Cancer Inst 85:1483–1489CrossRefPubMed
4.
Zurück zum Zitat Brooks JD, Metter EJ, Chan DW et al (2001) Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034–2038CrossRefPubMed Brooks JD, Metter EJ, Chan DW et al (2001) Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034–2038CrossRefPubMed
5.
Zurück zum Zitat Büntzel J, Micke O, Mücke R et al (2005) Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer – redox data. Trace Elem Electrolytes 22:211–215 Büntzel J, Micke O, Mücke R et al (2005) Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer – redox data. Trace Elem Electrolytes 22:211–215
6.
Zurück zum Zitat Büntzel J, Glatzel M, Kisters K (2006) Selenium as a radioprotector in head and neck cancer patients-first clinical results. Trace Elem Electrolytes 23:178–180 Büntzel J, Glatzel M, Kisters K (2006) Selenium as a radioprotector in head and neck cancer patients-first clinical results. Trace Elem Electrolytes 23:178–180
7.
Zurück zum Zitat Büntzel J, Micke O, Glatzel M et al (2009) Evaluation of the effect of selenium on radiation-induced toxicities in head neck cancer. J Clin Oncol 27(No 15 S): abstr. e20698 Büntzel J, Micke O, Glatzel M et al (2009) Evaluation of the effect of selenium on radiation-induced toxicities in head neck cancer. J Clin Oncol 27(No 15 S): abstr. e20698
8.
Zurück zum Zitat Chan JM, Oh WK, Xie W et al (2009) Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 27:3577–3583CrossRefPubMed Chan JM, Oh WK, Xie W et al (2009) Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 27:3577–3583CrossRefPubMed
9.
Zurück zum Zitat Clark LC, Combs GF, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J Am Med Assoc 276:1957–1963CrossRef Clark LC, Combs GF, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J Am Med Assoc 276:1957–1963CrossRef
10.
Zurück zum Zitat Dimitrov VN, Hay MB, Siew S et al (1987) Abrogation of Adriamycin-induced cardiotoxicity by selenium in rabbits. Am J Pathol 126:376–383PubMed Dimitrov VN, Hay MB, Siew S et al (1987) Abrogation of Adriamycin-induced cardiotoxicity by selenium in rabbits. Am J Pathol 126:376–383PubMed
11.
Zurück zum Zitat Gehrisch A, Doerr W (2007) Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol 183:36–42CrossRefPubMed Gehrisch A, Doerr W (2007) Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol 183:36–42CrossRefPubMed
12.
Zurück zum Zitat Duffield-Lillico AJ, Dalkin BL, Reid ME et al (2003) Nutritional prevention of cancer study group. BJU Int 91:608–612CrossRefPubMed Duffield-Lillico AJ, Dalkin BL, Reid ME et al (2003) Nutritional prevention of cancer study group. BJU Int 91:608–612CrossRefPubMed
13.
Zurück zum Zitat Fischer JL, Mihelc EM, Pollok KE et al (2007) Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 6:355–361CrossRefPubMed Fischer JL, Mihelc EM, Pollok KE et al (2007) Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 6:355–361CrossRefPubMed
15.
Zurück zum Zitat Kasseroller R (1998) Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 18:2227–2230PubMed Kasseroller R (1998) Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 18:2227–2230PubMed
16.
Zurück zum Zitat Kellen E, Zeegers M, Buntinx F (2006) Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 13:1180–1184CrossRefPubMed Kellen E, Zeegers M, Buntinx F (2006) Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 13:1180–1184CrossRefPubMed
17.
Zurück zum Zitat Knekt P, Aromaa A, Mantela J (1990) Serum selenium and subsequent risk of cancer among Finnish men and woman. J Natl Cancer Inst 82:864–868CrossRefPubMed Knekt P, Aromaa A, Mantela J (1990) Serum selenium and subsequent risk of cancer among Finnish men and woman. J Natl Cancer Inst 82:864–868CrossRefPubMed
18.
Zurück zum Zitat Lanfear J, Fleming J, Wu L et al (1994) The selenium metabolite selenodiglutathion induces p53 and apoptosis: relevance to the chemopreventive effects of selenium. Carcinogenesis 15:1387–1392CrossRefPubMed Lanfear J, Fleming J, Wu L et al (1994) The selenium metabolite selenodiglutathion induces p53 and apoptosis: relevance to the chemopreventive effects of selenium. Carcinogenesis 15:1387–1392CrossRefPubMed
19.
Zurück zum Zitat Last KW, Cornelius V, Delves T et al (2003) Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin‘s lymphoma. J Clin Oncol 21:2335–2341CrossRefPubMed Last KW, Cornelius V, Delves T et al (2003) Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin‘s lymphoma. J Clin Oncol 21:2335–2341CrossRefPubMed
20.
Zurück zum Zitat Last K, Maharaj L, Perry J et al (2006) The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol 17:773–779CrossRefPubMed Last K, Maharaj L, Perry J et al (2006) The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol 17:773–779CrossRefPubMed
21.
Zurück zum Zitat Lippmann SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51CrossRef Lippmann SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51CrossRef
22.
Zurück zum Zitat Micke O, Bruns F, Mücke R et al (2003) Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 56:40–49PubMed Micke O, Bruns F, Mücke R et al (2003) Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 56:40–49PubMed
23.
Zurück zum Zitat Micke O, Bruns F, Glatzel M et al (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. European Journal of Integrative Medicine 1:22–30 Micke O, Bruns F, Glatzel M et al (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. European Journal of Integrative Medicine 1:22–30
24.
Zurück zum Zitat Moyad MA (2002) Selenium and vitamin E supplements for prostate cancer: Evidence or embellishment? Urology 59:9–19CrossRefPubMed Moyad MA (2002) Selenium and vitamin E supplements for prostate cancer: Evidence or embellishment? Urology 59:9–19CrossRefPubMed
25.
Zurück zum Zitat Mücke R, Micke O, Schönekaes KG (2000) Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 17:119–123 Mücke R, Micke O, Schönekaes KG (2000) Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 17:119–123
26.
Zurück zum Zitat Mücke R, Büntzel J, Glatzel M et al (2009) Postoperative serum and whole blood selenium levels in patients with squamous cell and adeno-carcinomas of the uterus after curative surgical treatment. Trace Elem Electrolytes 26:78–82 Mücke R, Büntzel J, Glatzel M et al (2009) Postoperative serum and whole blood selenium levels in patients with squamous cell and adeno-carcinomas of the uterus after curative surgical treatment. Trace Elem Electrolytes 26:78–82
27.
Zurück zum Zitat Mücke R, Schomburg L, Glatzel M et al (2010) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 75 Mücke R, Schomburg L, Glatzel M et al (2010) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 75
28.
Zurück zum Zitat Papp LV, Lu J, Holmgren A et al (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9:775–806CrossRefPubMed Papp LV, Lu J, Holmgren A et al (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9:775–806CrossRefPubMed
29.
Zurück zum Zitat Patchen ML, MacVittie TJ, Weiss JF (1990) Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys 18:1069–1075PubMed Patchen ML, MacVittie TJ, Weiss JF (1990) Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys 18:1069–1075PubMed
30.
Zurück zum Zitat Pawlowicz Z, Zachara BA, Trafikowska U et al (1991) Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis 5:272–277 Pawlowicz Z, Zachara BA, Trafikowska U et al (1991) Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis 5:272–277
31.
32.
Zurück zum Zitat Schomburg L, Koehrle J (2007) Selenium: benefits and risks. MMW Fortschr Med 149:34–36PubMed Schomburg L, Koehrle J (2007) Selenium: benefits and risks. MMW Fortschr Med 149:34–36PubMed
33.
Zurück zum Zitat Shu-You Y, Ya-Jun Z, Wen-Guang Li et al (1991) A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 29:289–294CrossRef Shu-You Y, Ya-Jun Z, Wen-Guang Li et al (1991) A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 29:289–294CrossRef
34.
Zurück zum Zitat Torun M, Aldemir H, Yardim S (1995) Serum selenium levels in various cancer types. Trace Elem Electrolytes 12:186–190 Torun M, Aldemir H, Yardim S (1995) Serum selenium levels in various cancer types. Trace Elem Electrolytes 12:186–190
35.
Zurück zum Zitat Vermeulen N, Baldew GS, Los G et al (1993) Reduction of cisplatinum nephrotoxicity by sodium selenite. Drug Metab Dispos 21:30–36PubMed Vermeulen N, Baldew GS, Los G et al (1993) Reduction of cisplatinum nephrotoxicity by sodium selenite. Drug Metab Dispos 21:30–36PubMed
36.
Zurück zum Zitat Vunta H, Davis F, Palempalli UD et al (2007) The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. J Biol Chem 282:17964–17973CrossRefPubMed Vunta H, Davis F, Palempalli UD et al (2007) The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages. J Biol Chem 282:17964–17973CrossRefPubMed
37.
Zurück zum Zitat Weijl NI, Elsendoorn TJ, Lentjes EG et al (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40:1713–1723CrossRefPubMed Weijl NI, Elsendoorn TJ, Lentjes EG et al (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40:1713–1723CrossRefPubMed
38.
Zurück zum Zitat Yu SY, Mao BL, Xiao P et al (1990) Intervention trial with selenium for the prevention of lung cancer among tin miners in yunnan, china. A pilot study. Biol Trace Elem Res 24:105–108CrossRefPubMed Yu SY, Mao BL, Xiao P et al (1990) Intervention trial with selenium for the prevention of lung cancer among tin miners in yunnan, china. A pilot study. Biol Trace Elem Res 24:105–108CrossRefPubMed
39.
Zurück zum Zitat Zimmermann T, Leonhardt H, Kersting S et al (2005) Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res 106:193–203CrossRefPubMed Zimmermann T, Leonhardt H, Kersting S et al (2005) Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res 106:193–203CrossRefPubMed
Metadaten
Titel
Komplementärer Seleneinsatz in der Onkologie
verfasst von
Dr. R. Mücke
L. Schomburg
J. Büntzel
U. Gröber
P. Holzhauer
O. Micke
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 2/2010
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-009-1762-5

Weitere Artikel der Ausgabe 2/2010

Der Onkologe 2/2010 Zur Ausgabe

Außer der Reihe

TNM-System 2010

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.